News Overview
August 27, 2008
New Bayer CropScience active ingredient approved in Romania:
Thiencarbazone-methyl registered in first market
Annual sales potential of more than EUR 100 million for new corn herbicide » more
Thiencarbazone-methyl registered in first market
Annual sales potential of more than EUR 100 million for new corn herbicide » more
August 21, 2008
Further expansion of activities in China:
Bayer MaterialScience starts construction of a world-scale TDI plant in Shanghai
Annual capacity of 250,000 metric tons approved / Capacity can be increased to 300,000 metric tons per year / Start-up planned for 2010 » more
Bayer MaterialScience starts construction of a world-scale TDI plant in Shanghai
Annual capacity of 250,000 metric tons approved / Capacity can be increased to 300,000 metric tons per year / Start-up planned for 2010 » more
August 19, 2008
Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Study patients, on average, received only two additional doses following a 12-week fixed dosing period » more
Study patients, on average, received only two additional doses following a 12-week fixed dosing period » more
August 12, 2008
Excellence in the Field of Communications Honored
Bayer’s Annual Report Receives International Praise
» more
Bayer’s Annual Report Receives International Praise
» more
July 31, 2008
Bayer appoints Greg Babe as new CEO for U.S. Organisation
Predecessor Dr. Attila Molnar to retire » more
Predecessor Dr. Attila Molnar to retire » more
July 30, 2008
Interim report for the second quarter of 2008
Bayer continues its success
Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million / Full-year guidance for CropScience raised again / Group earnings forecast confirmed » more
1:09 min.
Bayer continues its success
Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million / Full-year guidance for CropScience raised again / Group earnings forecast confirmed » more
1:09 min.
July 30, 2008
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure » more
1:23 min.
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure » more
1:23 min.
July 28, 2008
Another milestone for cancer drug from Bayer and Onyx:
Nexavar Approved for Treatment of Liver Cancer in China
Nexavar is First Approved Systemic Therapy to Treat the Disease » more
1:17 min.
Nexavar Approved for Treatment of Liver Cancer in China
Nexavar is First Approved Systemic Therapy to Treat the Disease » more
1:17 min.
July 25, 2008
Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
Final approval from the European Commission expected within the next few months » more
1:36 min.
Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
Final approval from the European Commission expected within the next few months » more
1:36 min.
July 25, 2008
Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma
Dr. Bernd Metzner to become new Board member of Bayer’s pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following the successful integration of Bayer Schering Pharma » more
Dr. Bernd Metzner to become new Board member of Bayer’s pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following the successful integration of Bayer Schering Pharma » more
July 8, 2008
Innovative active ingredient provides reliable weed protection for corn:
Tembotrione from Bayer CropScience approved in Brazil
Launch of Soberan® planned for 2008 » more
Tembotrione from Bayer CropScience approved in Brazil
Launch of Soberan® planned for 2008 » more
July 2, 2008
Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market » more
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market » more
July 2, 2008
Bayer Expands Hemophilia Portfolio
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform » more
1:36 min.
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform » more
1:36 min.
June 24, 2008
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected » more
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected » more
June 23, 2008
Bayer’s Belford Roxo site near Rio de Janeiro celebrates 50th anniversary of its founding
Bayer plans to invest EUR 100 million in Brazil
Wenning: “Brazil is our biggest market in Latin America” » more
2:03 min.
Bayer plans to invest EUR 100 million in Brazil
Wenning: “Brazil is our biggest market in Latin America” » more
2:03 min.
June 23, 2008
New Bayer technology reduces power consumption and CO2 emissions by 30 percent:
Bayer receives Environmental Award from the Federation of German Industries
Energy-efficient process recycles chlorine from hydrochloric acid / Industrial application in Germany and China / Bayer Management Board member Dr. Plischke: “Increase in energy efficiency brings economic and ecological benefits” » more
1:49 min.
Bayer receives Environmental Award from the Federation of German Industries
Energy-efficient process recycles chlorine from hydrochloric acid / Industrial application in Germany and China / Bayer Management Board member Dr. Plischke: “Increase in energy efficiency brings economic and ecological benefits” » more
1:49 min.
June 20, 2008
In recognition of contributions to German-American economic relations
Bayer CEO Werner Wenning receives prestigious McCloy Award
Former German Foreign Minister Hans-Dietrich Genscher presents the honor in New York » more
2:17 min.
Bayer CEO Werner Wenning receives prestigious McCloy Award
Former German Foreign Minister Hans-Dietrich Genscher presents the honor in New York » more
2:17 min.
June 16, 2008
Pilot plant for future-oriented technology opens in Halle:
Bayer will use tobacco plants to produce medicines
First development candidate from the new plant for cancer indication non-Hodgkin’s lymphoma – Clinical phase I could start in 2009 / Bayer has invested over EUR 10 million in Halle since 2006 » more
1:29 min.
Bayer will use tobacco plants to produce medicines
First development candidate from the new plant for cancer indication non-Hodgkin’s lymphoma – Clinical phase I could start in 2009 / Bayer has invested over EUR 10 million in Halle since 2006 » more
1:29 min.
June 9, 2008
Presentation of new Sustainable Development Report in Berlin
Bayer Climate Program makes great advances
Climate protection projects rigorously implemented / Commitment to global health care provision / EUR 45 million spent annually to support 300 social projects worldwide / EUR 500,000 per year alone to support schools in the local communities / Report meets highest international standard » more
Bayer Climate Program makes great advances
Climate protection projects rigorously implemented / Commitment to global health care provision / EUR 45 million spent annually to support 300 social projects worldwide / EUR 500,000 per year alone to support schools in the local communities / Report meets highest international standard » more
June 5, 2008
Award sponsored by the Association of German Medical Journalists (VDMJ) and Bayer HealthCare AG
European Journalists’ Prize goes to Poland and Germany
Pawel Walewski honored for his report on the problems that cancer patients have with coping / Anahita Parastar receives prize for her report “Coma – is there a way back to life?” » more
European Journalists’ Prize goes to Poland and Germany
Pawel Walewski honored for his report on the problems that cancer patients have with coping / Anahita Parastar receives prize for her report “Coma – is there a way back to life?” » more